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Retroviral matrix and lipids, the intimate
interaction
Elise Hamard-Peron, Delphine Muriaux*
Abstract
Retroviruses are enveloped viruses that assemble on the inner leaflet of cellular membranes. Improving biophysical
techniques has recently unveiled many molecular aspects of the interaction between the retroviral structural
protein Gag and the cellular membrane lipids. This interaction is driven by the N-terminal matrix domain of the
protein, which probably undergoes important structural modifications during this process, and could induce
membrane lipid distribution changes as well. This review aims at describing the molecular events occurring during
MA-membrane interaction, and pointing out their consequences in terms of viral assembly. The striking
conservation of the matrix membrane binding mode among retroviruses indicates that this particular step is most
probably a relevant target for antiviral research.
Introduction
Retroviruses are enveloped single-stranded RNA (+)
viruses; they include some human pathogens such as
human immunodeficiency virus (HIV), and oncoviruses
such as the murine leukemia virus (MLV). Regardless of
their diversity and the high divergence in their
sequences, they share functional and viral protein struc-
ture similarities. Their genome contains the three retro-
viral genes: gag, pol, and env, and regulatory proteins in
the case of complex retroviruses. One of the important
steps in the process of retoviral infection is the forma-
tion of new infectious particles. It consists of the assem-
bly of the viral core at the cellular membrane, budding,
and maturation of the viral particles. In this review, we
will focus especially on the events that occur at the
molecular level during the interaction between Gag and
membranes, more particularly between the Matrix
domain of retroviral Gag proteins and the phospholi-
pids, and we will place it in the context of the viral
assembly process. Retroviral assembly relies on the viral
Gag protein, and especially its ability to interact with
the viral genomic RNA (gRNA) and cellular membranes.
Gag is a polyprotein with three domains: the matrix
domain, MA, that binds membranes, the capsid domain,
CA, that contains Gag multimerization motifs and is
responsible for the viral capsid formation (see [1] for
review), and the nucleocapsid domain, NC, that recruits
the RNA genome and also promotes Gag multimeriza-
tion [2,3]. The assembly process most probably initiates
with the formation of a ribonucleoprotein complex com-
posed of a few Gag molecules and the gRNA, which is
going to interact with membranes [4,5]. Beta-retro-
viruses and spumaviruses are exceptions, that fully
assemble in the cytosol before reaching membranes (see
[6] for review on spumaviruses, and [7] for study on the
role of MA in promoting cytosolic assembly of M-
PMV). The formation of higher order Gag multimers
leads to the formation of the viral particle at the plasma
membrane, and subsequent budding and maturation,
which consist of the proteolytic cleavage of Gag and
structural rearrangement of the particle. The MA
domain is not only carrying Gag trafficking and mem-
brane binding determinants, but also dictating the speci-
ficity of the bound lipid. Many data have been recently
published partially unveiling the molecular mechanism
of MA lipid binding, enhancing the understanding of
the role played by MA during Gag membrane targeting
and assembly. In the light of the literature and our
experiences, this review aims at proposing biochemical
models for MA-lipid interactions for different retro-
viruses, and replacing the consequences of such interac-
tions in the context of retroviral assembly. We will
identify the elements conserved through retroviral evo-
lution, and those that are specific to particular retroviral
strains.
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Matrix proteins: a structural point of view
Despite low sequence similarity, MAs from different ret-
roviruses share a conserved function in anchoring the
viral Gag polyprotein to the plasma membrane. Indeed,
most Gag chimeras with heterologous MA domains
remain able to drive particle assembly [8-11]. One ele-
ment allowing the interaction with the cellular mem-
brane is N-terminal myristylation, a post-tranlational
modification found in MAs from all retroviral families
(myrMAs), including human immunodeficiency virus
(HIV) [12], human T-lymphotropic virus (HTLV) [13],
Mason-Pfizer monkey virus (M-PMV) [14] and exogen-
ous murine leukemia virus (MLV) strains [15,16]. This
myristate moiety is a common signal for membrane tar-
geting of proteins, as it can insert into membrane
bilayers. There are some exceptions, however, as Rous
sarcoma virus (RSV), Visna virus, caprine arthritis-ence-
phalitis virus (CAEV) and equine infectious anemia
virus (EIAV) MAs are not myristylated [14]. Therefore,
myristylation cannot be the only element involved in
this targeting. Structural analysis of MA domains offers
some clues for understanding its conserved biological
role regarding membrane anchoring. Matrix structures
from nine retroviruses have been resolved to date: HIV-
1 [17-20] and 2 [21], SIV [22], HTLV-2 [23], bovine leu-
kemia virus (BLV) [24], M-PMV [25], RSV [26], EIAV
[27], and MLV [28]. They are all made of a globular
core composed of four a-helices, whose overall organi-
zation is conserved among the retroviridae family
[29,30] as shown by the superimposition Figure 1A. In
the case of HIV-1, the unmyr-MA structure was
resolved both by NMR [17,18] and crystallography [19],
while the myr-MA structure was resolved by NMR only
[20]. HIV-1 unmyr-MA (as well as SIV, but neither
EAIV nor MLV MAs) crystallized as trimers, while it
appeared mainly monomeric in classical NMR condi-
tions. Overall structure was conserved between myr and
unmyr-MA, but some differences arose, notably in the
putative trimerization region and in the first alpha helix.
As suggested earlier by Zhou and Resh [31], Tang and
colleagues [20] showed that there is an equilibrium
between two conformations of HIV-1 myrMA in solu-
tion. In the myr[s] conformation, the myristate moiety is
sequestrated inside the core of the protein (see scheme
in Figure 1B). This is the conformation adopted by the
majority of myr-MA at a concentration of 150-200 μM.
The other conformation, myr[e], promotes the exposure
of the myristate and tends to assemble in trimers. This
conformation is probably close to the conformation
observed for unmyr-MA. The conversion from one state
to the other is entropically regulated [20]. In particular,
high concentration of MA (more than 400 μM) pro-
motes trimerization and stabilizes the myr[e] conforma-
tion. This will be extensively discussed in the next
sections. Whether these myr[s] and myr[e] conforma-
tions exist for other retroviral MAs has never been
demonstrated formally. However, a NMR study carried
out on EIAV-MA (which is not myristylated) evidenced
amino acid shifts at high MA concentration, and corre-
lated with an increase of the trimeric versus monomeric
state [32]. Even if no major conformation change was
noticed, this may correspond to an entropic switch
between two slightly different conformations, similar to
HIV. We, therefore, propose a new nomenclature for
the MA conformations, that can also apply for unmyris-
tylated MAs. By analogy with the enzymology, the mem-
brane-binding prone conformation will be denoted
hereafter as relaxed [R], while the other conformation
will be denoted as tensed [T] (Figure 1B). Another
important element of MA necessary for membrane
binding is most probably the highly basic region (HBR).
Indeed, an exposed patch of basic amino acids has been
observed or predicted on all retroviral MAs [30].
A comparison between structurally superimposed
Figure 1 A structural overview of retroviral MAs. (A): Structural superimposition of MLV (1MN8), RSV (1A6S) and HIV (1TAM) MA proteins.
Superimposition obtained using the combinatorial extension method (CE) and the image was generated with Viewer Pro software (Accelrys),
thanks to E. Derivery. (B): Scheme of the [T] to [R] switch. [T] conformation sequesters the myristate of myristylated MAs, and remains
monomeric, while [R] conformation associates in trimers and exposes the myristate (when present).
Hamard-Peron and Muriaux Retrovirology 2011, 8:15
http://www.retrovirology.com/content/8/1/15
Page 2 of 13
retroviral MAs shows that this domain “migrates” on the
surface of the protein, but is always found in the proxi-
mity of the N-terminus [30]. This supports the idea that
the N-terminus and the polybasic region of MA coop-
erate for efficient membrane binding, as HBR was
hypothetized to promote interaction of MA with acidic
phospholipid heads [30]. Moreover, other amino acids
could be involved in Gag membrane anchoring, such as
the N-terminal amino acids invovled in [T] to [R] con-
version in HIV-MA [33,34].
Acidic lipid binding: the biochemical
characterization
In cells, analysis confirmed that Gag membrane binding
depends on this bipartite signal for most retroviruses. On
one hand, the myristate moiety is, as expected, necessary
to ensure membrane binding for all myristylated MAs, as
shown for MLV [16,35], HIV [36], or M-PMV [37]. On
the other hand, mutations in the HBR disrupted Gag
membrane-binding and assembly of HIV [38-41], MLV
[42,43], feline immunodeficiency virus (FIV) [44], RSV
[45], HTLV-1 [46] and M-PMV [47], suggest that MA
may interact with acidic membrane lipids.
To precisely identify the lipids that interact with retro-
viral Gag proteins, researchers focused on the lipids
potentially present at the budding site. Phospholipids,
including glycerophospholipids and sphingolipids, are
the main components of cellular membranes, among
which the most abundant are phosphatidylcholine (PC)
and phosphatidylethanolamine (PE), both containing a
neutral polar head. Some less abundant species, how-
ever, like phosphatidyl serine (PS), phosphatidyl glycerol
(PG) or phosphatidylinositol phosphates (PIPs), contain
acidic polar heads (cf. Figure 2). Apart from phospholi-
pids, cellular membranes also contain other lipids, such
as cholesterol, and an important proportion of trans-
membrane proteins. The composition of a membrane
depends on its localization (internal/plasma membrane,
inner/outer leaflets, etc.) and defines its functionality.
Thus, retroviral assembly location restricts the panel of
lipids potentially involved in the interaction with MA.
Indeed, budding is mainly observed at the plasma
Figure 2 Some lipid components of the internal leaflet of cellular membranes. Main lipid components of the internal leaflet of cellular
membranes are represented: phosphatidylcholine (PC), Phosphatidylethanolamine (PE), phosphatidylserine (PS), Phosphatidylinositol phosphates
(here, PI(4,5)P2) and cholesterol. In membrane bilayers, the polar heads (top) face the cytosol, while the hydrophobic fatty acid chains (bottom)
face the hydrophobic tails of the other leaflets’s lipids.
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membrane for most retroviruses, including HIV [48], M-
PMV, MLV [42,49], FIV, RSV, HTLV, but may also
occur on internal membranes such as endosomes (see
[50] and [51] for review). Moreover, the MA domain of
Gag interacts with the inner leaflet of cellular mem-
branes, whose main lipids are PC, PE, PS, PIP (here PI
(4,5)P2), and cholesterol [52], thereby succeptible to
interact with MA (Figure 2).
Interaction between proteins and lipids can be studied
in vitro using biomimetic membranes, and in particular
large unilamellar vesicles (see [53] for review on using
LUVs). The dissociation constant (Kd) can be measured,
and corresponds to the lipid concentration at which half
the protein is associated with the lipids: the lower the
Kd, the higher the affinity. Most experiments were per-
formed using recombinant MA proteins, because purifi-
cation of the entire Gag protein is not easy. MA domain
is separated from the rest of Gag by a flexible linker,
thus isolated recombinant MA should recapitulate most
functions of MA domain in Gag. It must be taken into
account, however, that HIV-MA alone seems to have
decreased affinity for membranes in comparison to the
entire Gag [31]. Recombinant MA is also directly repre-
sentative of the maturated MA domain function in
mature particles and during early stage of viral infection.
As expected, purified recombinant MAs from RSV [54]
and HIV-1 [55,56] can bind containing an acidic phos-
pholipid, the phosphatidylserine (PS), which is an abun-
dant specy in the internal layer of cellular membranes.
The order of magnitude of the Kd measurements made
for recombinant RSV-MA and HIV-1 myristylated MA
(myrMA) were of 10-
3M, and about one order of magni-
tude lower upon forced dimerization of MA [54,55].
Nevertheless, the method used in these studies, i.e. LUV
flotation, may underestimate the actual affinity, as the
sucrose gradient may dilute the lipids. Indeed, we and
others reported a value closer to 10-
5M for unmyristy-
lated HIV MA (HIV unmyrMA) by sedimentation assay
[42] or by intrinsic fluorescence measurement [56,57].
Ehrlich and colleagues [56] showed that HIV-1 MA is
also able to bind in vitro to another basic phospholipid,
the phosphatidylglycerol (PG). These later studies were
contested, however, because the authors also observed a
binding of the CA domain of Gag to PG and PS that
other authors questioned [54]. Recently, Barrera and
colleagues [58] confirmed that CA has acidic lipid bind-
ing properties [58,59], rehabilitating the previous find-
ings. It was also reported that EIAV MA can interact
with PS (Kd <10-
6M at 0.1 M NaCl) and PC [60].
The binding of retroviral MAs to lipids was thus con-
sidered to be purely electrostatic, as the interaction with
PS was inhibited at high ionic strength. The Kd values
found would fit well with the computational models
considering electrostatic interaction between acidic
lipids and basic MAs [30]. These reported Kd values
would be rather low, though, to fully explain the binding
of Gag to the plasma membrane in cells, and multimeri-
zation was invoked to explain MA binding to mem-
branes [54,55].
Several retroviruses, however, show a dependency on a
particular acidic phospholipid, the PI(4,5)P2, for efficient
particle production in cells. These include HIV [61,62],
M-PMV [47] and MLV [42,62]. Phosphatidylinositol
phosphates are a family of acidic glycerophospholipids,
with a polar head made of an inositol ring that can be
mono-, bi-or tri-phosphorylated (Figure 2 shows the
example of PI(4,5)P2). The sub-cellular localization of
the different species is highly regulated by cellular
kinases and phosphatases, such that they stand as major
determinants of the identity of organelles’ membranes
(see [63], [64] and [65] for review).
The interaction between MAs and PI(4,5)P2 has been
observed in vitro by NMR (EIAV [32], HIV-1 [66] and
HIV-2 [21]), using LUVs (HIV-1 [67-69] and MLV [42]),
by mass spectrometric footprinting (HIV-1 [70]) and by
surface plasmon resonance (SPR)(HIV-1, [71]). The Kd
values measured by NMR were rather high for all tested
lentiviruses (EIAV, HIV-1, and HIV-2), ranging from 125
to 185 μM, and cannot account for membrane binding in
cells. It is noteworthy though that these interactions were
observed with short chain PIPs (Di-C4-PI(4,5)P2). In con-
trast, SPR analysis was performed both with Di-C4-and
Di-C8-PI(4,5)P2 (longer acyl chains), and Kd values
decreased significantly in the case of Di-C8-PI(4,5)P2,
suggesting that acyl chains are involved in the interaction
between MA and PI(4,5)P2 [71]. The Kd of this interac-
tion could not be calculated in the LUV systems, how-
ever, neither for the recombinant HIV MA domain
[42,55], nor for the recombinant RSV MA domain [54].
This suggests that unlike PS binding, the mechanism of
PIP/HIV-MA interaction could be more complex than a
simple electrostatic interaction. The region of HIV-MA
involved in the interaction with PI(4,5)P2 differs slightly
depending on the method used (NMR [66] or footprint-
ing [70]), but mapped to the HBR in both cases. New
NMR techniques, using reverse micelle encapsidation
instead of soluble lipids could settle it, but only prelimin-
ary results have been published to date [72].
We recently reported a definite different behavior in the
case of MLV-MA [42]. UnmyrMLV-MA was able to bind
PIPs-containing LUVs in a dose-dependant manner. An
interaction is observed not only with PI(4,5)P2, but also
with all the PIPs species, with Kd values ranging from 20
to 50 μM. To the contrary, unmyrMLV-MA does not bind
PS containing LUVs, even if the residues involved in the
interaction with PIPs map to the HBR. However, adding
PI(4,5)P2 and PS together in the same LUV dramatically
increased the affinity of MLV-MA for PI(4,5)P2, but not
Hamard-Peron and Muriaux Retrovirology 2011, 8:15
http://www.retrovirology.com/content/8/1/15
Page 4 of 13
for the other PIPs. Therefore, as for HIV, interaction with
PIPs appears to result from a specific interaction, rather
than a purely electrostatic mechanism [42].
Specificity and regulation of the interaction with
acidic phospholipids
In the light of the data presented above, we can ques-
tion the specificity and the biological relevance of the
interaction of retroviral Gag with the different acidic
phospholipid species, as MA can interact in vitro with
different acidic phospholipids, with important differ-
ences in Kd and interaction mode.
The lipidomics data emerging from the analysis of
viral particles, however, seems to confirm the specificity
for both PI(4,5)P2 and PS, as they are highly enriched in
MLV particles [73]. This is consistent with the in vitro
data obtained with MLV-MA, showing that there is in
fact a cooperation between PI(4,5)P2 and PS which
allows strong MA anchoring to the membrane. Indeed,
even if MLV-MA can bind any PIPs but not PS-contain-
ing LUVs, the protein actually displayed a strong stereo-
specificity for PI(4,5)P2, but exclusively when PS is
added to the same LUV (resulting in a fourfold decrease
in Kd, [42]). Thus, MA probably interacts with both PI
(4,5)P2 and PS, but we hypothesize that PS binding may
occur only after initial docking of MA on the PI(4,5)P2.
In HIV particles, PI(4,5)P2 is enriched, while PS is pre-
sent at high concentrations. Together with data emer-
ging from MLV study, these results indicate that in vitro
binding of HIV-MA to both PI(4,5)P2 and PS may be
biologically relevant. Other families of lipids may also
regulate MA association with membranes. In particular,
HIV myrMA show more affinity for cholesterol-contain-
ing biomimetic membranes [57], and cholesterol
enhances the binding specificity of HIV-MA to PI(4,5)P2
[67], in accordance with the finding that retroviruses
can bud in cholesterol-enriched membrane domains
such as lipid rafts [74-76].
Surprisingly enough, another element, the RNA, was
recently found to be involved in the regulation and the
specificity of HIV-MA membrane binding [69]. Indeed,
HIV-MA has long been known to bind RNA efficiently
in vitro [67,70,77-79], as does BLV-MA [80] and RSV-
MA [81]. Moreover, HIV-MA specifically interacts with
RNA, bearing a high degree of homology to a region
within the Pol open reading frame of the HIV-1 gen-
ome, suggesting that the RNA molecule interacting with
MA in cells might be the viral gRNA [79]. Interestingly,
the basic residues of HIV-1 MA involved in the interac-
tion with RNA are also necessary for PI(4,5)P2 binding
[66,70,77,79]. Thus, RNA might be a competitive inhibi-
tor of the interaction with PI(4,5)P2. As a matter of fact,
Chukkapalli and colleagues observed that RNAse treat-
ment increased binding of Gag to both neutral and
acidic LUVs (PC, +/- PS, +/- PI(4,5)P2) [69]. The
hypothesis is that RNA would inhibit the entropic
switch, stabilizing the [T] conformation (Figure 3Ab),
thus preventing membrane-binding in general. On the
other hand, Alfadhli and colleagues [67] simultaneously
found that PI(4,5)P2 is the only lipid that can remove
nucleic acids bound to HIV-1 myrMA recombinant pro-
tein. This favors the idea that RNA would ensure the
specificity of the interaction of MA with the PI(4,5)P2,
which therefore appears as a relevant cellular partner of
Gag during the assembly process, allowing MA to
switch from a “transport” [T] conformation to a “mem-
brane binding” [R] conformation. RNA-meditated regu-
lation of HIV-MA binding to PI(4,5)P2 seems to be
supported by the data emerging from in cellulo studies.
A functional link between the genomic RNA exporting
pathway and the HIV-1 MA-driven assembly has been
established recently, even if the precise mechanism has
not been elucidated [82-85]. Whether gRNA plays a role
in MA/lipid interaction for other retroviruses is not
known as yet. EIAV or MLV does not seem to have the
same dependency on gRNA export pathway for proper
assembly [84,85] as compared to HIV-1. In contrast,
RSV-MA is able to interact with both PS [54] and RNA
[81]. The measured affinity for PI(4,5)P2 was found to
be low in the case of RSV MA alone [54], but given the
results obtained with HIV-MA, further investigation
could prove useful. Thus, from an evolutionary point of
Figure 3 A model for [T] to [R] equilibrium in different
conditions. Some elements are susceptible to influence the MA [T]
vs [R] equilibrium, in the context of MA alone (in the mature
particle, during the early step of infection, or in vitro), or as a
domain of the Gag polyprotein. The “initial” equilibrium (in solution,
purified protein, concentration around 1 μM) between the [T] and
[R] conformations of HIV (A) and MLV (B) MAs (a) or Gag (b) are
depicted, the size of the protein representing the relative amount of
each form. The factors susceptible to induce a majority of a given
conformation are written in bold characters. Others, such as PI(4,5)P2
in the case of HIV-MA, are only able to (slightly) displace the
equilibrium, even at a saturating concentration (Aa).
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view, it would be interesting to determine if these regu-
lation modes involving PI(4,5)P2 and RNA are conserved
among retroviruses, including those lacking MA
myristylation.
In summary, we have proposed a model in which two
different retroviral MAs use alternative mechanisms to
bind membrane lipids, but end up with the same lipid
specificity. MLV-MA is able to interact initially with PI
(4,5)P2, and this interaction triggers a conformational
modification that allows PS binding. In contrast, HIV-
MA would have initially low affinity for PI(4,5)P2, espe-
cially in the presence of gRNA [69]. However, PI(4,5)P2
seems to be the only compound able to compete with
RNA for HIV-MA binding [67], and once RNA is
removed, HIV-MA would be able to interact both with
PI(4,5)P2 and PS, and this interaction may be stabilized
by other elements, as discussed in the next section.
Therefore, in spite of different lipid binding modes, the
specificity of binding could be highly conserved among
retroviruses.
Let’s switch again! Stabilization of the [R]
conformation
The interaction of retroviral MAs with PI(4,5)P2 seems
to be a conserved, highly specific, and regulated feature
among retroviruses. As previously mentioned, PI(4,5)P2
binding seems to be associated with conformational
changes, as shown by NMR for HIV-1 MA [66] and
EIAV-MA [86]. For HIV, it corresponds to the myr[s]
and myr[e] conformations ([T] and [R] respectively) evi-
denced by structural studies [20], and it is probably also
the case for EIAV except that it is not myristylated.
This supports a pre-existing hypothesis first proposed
by Zhou et al [31]: the existence of a “myristyl switch”,
that is actually an entropic equilibrium between the [T]
conformation that sequesters the myristate inside the
protein, and the [R] conformation that promotes trimer-
istation and exposure of the myristate moiety allowing
its insertion in the cellular membranes. A refinement of
this model was proposed by Saad and colleagues, as the
NMR data on HIV-MA suggested that the insertion of
the myristate into the lipidic bilayer may be compen-
sated by the extraction of the 2’ fatty acid chain of the
PI(4,5)P2 out of the membrane, that would then be
sequestrated into the hydrophobic core of the MA
domain (Figure 4Ad) [66]. Anraku and colleagues com-
pared the affinity of HIV-1 MA and Gag for phophory-
lated inositol ring alone and for medium length fatty
acid chain lipids (Di-C8-PI(4,5)P2), in order to compare
the relative contribution of electrostatic interactions
(with inositol phosphate ring) and hydrophobic interac-
tions (with acyl chains) [71]. In accordance with the
data from Saad et al. [66], acyl chains were found to
have a major contribution in the interaction. This
model, however, is built on data obtained with short
chain fatty acids, and needs further confirmation in lipid
bilayer conditions.
As a model for HIV-MA/PI(4,5)P2 interaction, we pro-
pose that the [T] conformation has a high affinity for
RNA, and a low affinity for PI(4,5)P2. On the contrary,
the [R] conformation has a high affinity for PI(4,5)P2. PI
(4,5)P2 would compete with RNA for HIV-MA binding
as recently proposed [69,87] and its interaction with
MA would in turn stabilize the [R] conformation as
shown by Saad and colleagues [66] (Figure 3Aa). In this
model, PI(4,5)P2 has two roles: in addition to being the
“substrate” (i.e. the bound molecule), it is also an effec-
tor, stabilizing the binding prone conformation, [R] (Fig-
ure 3Aa). In other words, PI(4,5)P2 is able to displace a
pre-exiting equilibrium toward the [R] conformation, as
suggested by Tang et al [20]. Symmetrically, RNA would
have an “allosteric inhibitor” effect in stabilizing the [T]
conformation (Figure 3Aa). This property may prevent a
specific binding to membranes lacking PI(4,5)P2. This
model could explain why many authors were unable to
measure the affinity of HIV-1 MA for PI(4,5)P2 in the
LUV system [42,55]. At low HIV-MA concentrations
(from 1μM to 20μM), the equilibrium would be only
slightly displaced toward the [R] conformation, even at a
saturating PI(4,5)P2 concentration (Figure 3Aa[42,54]).
The [T] conformation had very low affinity for the lipid;
we and others concluded that the affinity of MA for PI
(4,5)P2 was negligible in these conditions [42,55]. Many
other elements could also influence the [T] to [R] equili-
brium in vivo, to allow specific interaction of Gag with
membranes. As mentioned earlier, a high concentration
of MA promotes trimerization, and at the same time
stabilizes the [R] conformation [20] (cf. Figure 3Aa). In
addition, multimerization of Gag seems to correlate with
the appearance of the [R] state, as multimerizing regions
in CA promote myristate exposure [20] and increase
lipid binding of MA-CA constructs [55]in vitro. In cells,
it has been shown that proteolytic cleavage of Gag
induces partial dissociation of p17MA from the mem-
brane, confirming that uncleaved Gag stabilizes the [R]
conformation of MA [31,88,89]. Another parameter that
seems to influence the [T] to [R] transition is pH, as
shown recently by Fledderman et al. [90]. High pH sta-
bilizes the [T] form, while acidification favors myristate
exposure. In addition, the same laboratory also reported
that Calmodulin (CalN), a Ca2+ sensor protein determi-
nant that interacts with HIV MA, promotes the myristyl
switch [91].
The equilibrium constant between the [T] and [R] con-
formations also seems to vary greatly from one MA to
another. As a matter of fact, in NMR conditions (high
MA concentration, around 0.5 mM), HIV-1 and HIV-2
MAs behave differently in the presence of PI(4,5)P2, the
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[R] conformation remains undetectable for HIV-2 MA
[21], unlike HIV-1 [66]. As far as other viruses are con-
cerned, less data are available. It is possible that PI(4,5)P2
also stabilizes an [R] conformation of EIAV-MA as sug-
gested by 2-D NMR data obtained by Chen et al [86],
showing a slight amino acid shift upon PI(4,5)P2 binding.
In contrast, MLV MA may display a more complex beha-
vior. We were able to calculate two Kd values for MA/PI
(4,5)P2 interaction, either in the presence or absence of
PS. The [T] conformation might be able to bind PI(4,5)P2
with a Kd of 25 μM, while the [R] conformation might be
stabilized by the presence of PS, allowing PI(4,5)P2 to
switch to the extended lipid conformation, with a result-
ing Kd value approaching 5 μM (Figure 3Ba) [42].
Another hypothesis is that the majority of MA is already
in the [R] conformation, and that PS modulates the affi-
nity of the interaction with PI(4,5)P2.
The switch from the [T] to the [R] conformation may
have further implications at the level of the entire Gag
protein, thus influencing the assembly process. Indeed,
Datta et al. recently proposed a model in which HIV-
Gag would be in a bent conformation in solution, with
MA and NC in close proximity [92,93] (Figure 3Ab).
This model is supported by the fact that both NC and
MA can bind IP6 (an inositol ring containing six phos-
phorylations, thus somewhat homologous to PI(4,5)P2)
in vitro, and is consistent with hydrodynamic and small-
angle neutron scattering data. This is also in agreement
with the idea that RNA can bind both NC and MA
[67,70,77-79]. This is not compatible, however, with the
immature particle organization, in which Gag is in an
extended rod-shaped conformation [94]. Consequently,
the authors propose that viral assembly is coupled with
major conformational modifications of Gag (Figure
Figure 4 Models for retroviral Gag membrane binding. Aa and Ba: formation of Gag dimers, association on gRNA. Ab: inhibition of HIV-MA
membrane binding by gRNA. Ac: removal of gRNA resulting from competition between gRNA and PI(4,5)P2 for HIV-MA binding. Ad: Stabilization
of the [R] conformation of MA by interaction with PI(4,5)P2, Gag trimerization, stabilization of membrane anchoring by PS, lateral targeting of
Gag to assembly microdomains. Bb: Binding of MLV-MA to PI(4,5)P2. Bc: Secondary binding of MLV-MA to PS, stabilization the MA [R]
conformation. Bd: lateral targeting of Gag to assembly microdomains.
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3Ab). The same group showed that correct in vitro
assembly of viral like particles necessitates both RNA
and IP6 (that can be considered as an analog of PI(4,5)
P2). It is still the case when the NC domain is replaced
by a multimerization domain such as a leucine zipper,
suggesting that RNA not only plays a role in assembly
via its interaction with the NC domain, but probably
also at the level of the MA domain [95].
The ability of HIV-Gag to auto-assemble into viral-like
particles in vitro seems to be linked with a switch from
Gag dimers to Gag trimers that can be mediated by IP6
[93,95]. As it has been shown that PI(4,5)P2 promotes
HIV-MA trimeric association [87], the effect of IP6
addition could mimic the effect of PI(4,5)P2 binding in
cells, in stabilizing the [R] conformation and promoting
the formation of MA trimers. This could further trigger
Gag structural reorganization via dimer to trimer transi-
tion (Figure 4Ad). A similar mechanism could drive the
assembly of all retroviruses, as other retroviral MAs
have multimerization properties upon PI(4,5)P2 binding.
For exemple, MLV-MA multimerizes in the presence of
PI(4,5)P2 under certain conditions (unpublished personal
data), and EIAV-MA forms trimers [32].
MLV-Gag, however, seems to differ in some points
from lentiviral Gag proteins. Datta et al. showed that
in vitro recombinant MLV-Gag is readily in a rod-
shaped conformation in solution, with a much more
rigid structure (Datta, Zuo, Campbell, Wang, Rein:
Personnal communication) (Figure 3Bb). This property
might argue for an absence of an RNA mediated main-
tenance of the [T] conformation for MLV-MA. This
correlates with the fact that the [R] conformation of
MLV-MA appears more stable, as 100% of MLV-Gag
is associated with membranes in cells [42], in contrast
with HIV-Gag which is no more than 60% membrane
bound [96]. However, we cannot exclude the possibility
that RNA could regulate the interaction of MLV-MA
with lipids.
The mechanisms of interaction between retroviral MAs
and lipids are quite original, and whether some particula-
rities of these binding modes can also apply to other viral
or cellular proteins is not known. For instance, other ret-
roviral proteins could interact with lipids using a similar
mechanism. For example, Nef and Tat, two regulatory
proteins of HIV, also bind membranes. In fact, Nef is a
myristylated protein able to bind acidic phospholipids,
but the curvature of the membrane induced upon Nef
binding is not consistent with the extraction of a fatty
acid out of the membrane [97] as in the model proposed
for HIV-MA [66]. A myristyl switch mechanism is still
possible, however, as the binding of Nef to biomimetic
membranes is a biphasic process, with a first phase of
electrostatic interaction with acidic phospholipids, and a
second phase of structural modifications (in particular,
the formation of an amphiphatic helix) [97]. As for Tat, it
was recently shown that it also interacts with PI(4,5)P2
before crossing the plasma membrane and being secreted
into the extracellular environment [98-100].
Conclusion: Cellular consequence of Gag binding
to PI(4,5)P2 and PS
Taking all the previously discussed data together
allowed us to propose a model for the role played by
MA during HIV and MLV assembly initiation, at the
molecular level (Figure 4). In this model, Gag first poly-
merizes on gRNA (Aa and Ba), but adopts a bent con-
formation in the case of HIV (Aa), with both MA and
NC interacting with gRNA, while MLV-Gag is readily in
a rod-shaped conformation (Ba). For both viruses, the
[T] conformation of MA is initially dominant, with myr-
istate trapped in the protein core. When HIV-MA
reaches PM (Ab), PI(4,5)P2 is able to compete with
gRNA for MA binding (Ac). Removal of gRNA and
interaction with PI(4,5)P2 stabilize the [R] conformation
of MA (exposed myristate), which in turn promotes the
trimerization and the reorganization of Gag into its rod-
shapped conformation (Ad). The presence of PS could
stabilize the interaction between MA and PI(4,5)P2 (Ad).
Gag would then be laterally targeted to membrane
microdomains containing high levels of saturated lipids,
such as lipid rafts (Ad). In the case of MLV, initial bind-
ing to PI(4,5)P2 (Bb) is followed by a secondary binding
to PS (Bc) that would further stabilize the [R] conforma-
tion of MA, exposing the myristate. Like HIV, lateral
targeting of Gag to rafts or other microdomains is likely
to occur afterwards (Bd).
These mechanistic observations are useful to re-evalu-
ate the data available regarding assembly and budding
localization in cells. Analysis of the retroviral particle
envelope content evidenced that budding membranes
resemble the plasma membrane in terms of lipid compo-
sition [73,75,101-105]. The ratio between lipids, however,
differs from the average plasma membrane composition.
In particular, viral particles of HIV and MLV are
enriched not only in PI(4,5)P2 and PS, but also in choles-
terol, ceramides, GM3 and sphingolipids [73]. This can
reflect the fact that viral particles are produced in specific
membrane microdomains. Moreover, HIV virions are
also enriched in lipid raft markers such as GPI-anchored
proteins [106], actin and actin-associated proteins, such
as Ezrin-Radixin-Moesin proteins (ERMs) [107,108], and
in tetraspanins [108-116]. ERM and tetraspanins are also
found in particles of MLV [107,117,118]. In consequence,
retroviral budding has been proposed to occur preferen-
tially in two types of membrane microdomains associated
with actin cytoskeleton: lipid rafts and tetraspanin
enriched microdomains (TEMs). There is a spatial and
functional distinction, however, between these two kind
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of domains [119-121], even if they are adjacent and may
interact [122-124].
Lipid rafts are membrane domains enriched in choles-
terol and sphingolipids, but can also be enriched in PI
(4,5)P2 and PS under specific conditions [125-128].
Rafts were initially identified as detergent-resistant
membranes, and this property was widely utilized to
characterize raft-associated lipids and proteins, includ-
ing HIV-Gag [74,129-137], MLV-Gag [76,136] and
HTLV-1-Gag [136,138]. The existence in living cell, the
exact nature, and the actual size of lipid rafts has, how-
ever, been intensely debated over the past decades. The
current consensus is that lipid rafts are nanoscale con-
centrations of specific lipids, notably cholesterol and
sphingolipids, and proteins (reviewed in [128,139]).
Their size is around 10 to 20 nm but they can coalesce
and organize membrane bioactivity in many ways.
The association of HIV-Gag with lipid rafts depends
on both membrane association signals of MA, the myr-
istate and the HBR (reviewed in [140,141]). Lower order
multimerization is also necessary because the association
of CA mutants with lipid rafts is delayed [74], however,
higher order association appears to be dispensable as
demonstrated by NC mutants [142]. Lipid raft targeting
is a slower process than membrane association, giving
the idea that initial docking of Gag at the plasma mem-
brane is followed by lateral transport to assembly micro-
domains as proposed by Ono and Freed [74].
Saad and colleagues [66] proposed a very elegant
model in agreement with a preferential budding of HIV
in raft microdomains. Their NMR data suggests that the
2’-fatty acid of the PI(4,5)P2 is extracted from the mem-
brane bilayer upon MA binding, and sequestrated inside
the protein, in the same hydrophobic pocket the myris-
tate occupied. Unlike the 2’-chain, the 1’-chain is usually
saturated, as is the myristate (cf. Figure 4). If this model
proves to be correct, Gag would then be anchored to
the membrane via two saturated chains (myristate and
1’-chain) and this could result in a lateral targeting of
Gag to lipid rafts, where saturated lipids are enriched
(Figure 4d, Bd).
The trapping of PI(4,5)P2 into lipid rafts by Gag may
have important consequences in terms of cellular
responses. Indeed, in non-infected cells, it seems that
the ratio of raft-associated PI(4,5)P2 versus raft-excluded
PI(4,5)P2 is finely regulated. Any modification of one
pool seems to have profound consequences, in particular
on cytoskeleton remodelling, cell morphology and mod-
ulation of signaling pathways, such as the PI3K-Akt
pathway [143].
Whether Gag, and in particular the MA domain, is
able to aggregate lipid raft microdomains (directly or
indirectly) or bind to pre-formed platforms is not as yet
known, even if recent findings argue for dynamic
aggregation of raft components by Gag [116]. Annexin 2
could potentially play a role, as this protein interacts
with Gag [108,144] and is able to aggregate lipids, in
particular cholesterol, PS, and PI(4,5)P2 [145,146]. Other
viral proteins may be involved too. It was recently
shown that gPr80[gag], a long glycosylated form of MLV-
Gag, increases the release of MLV and HIV particles via
lipid rafts [76]. A similar role has been observed for
HIV-Nef [147], which also increases the “raft-like” prop-
erties of HIV particles [105] and modifies the choles-
terol metabolism of producer cells [148]. However, it is
not known how these two proteins act to relocate
assembly in these microdomains.
On the other hand, several authors have reported that
retroviral assembly occurs in association with tetraspa-
nins [108-116,149-151]. Some tetraspanins can modulate
viral infectivity and regulate cell to cell transmission
[115], while the role of others, such as CD63, is currently
debated [152]. The tetraspanins are a family of small
transmembrane proteins that operate as major lateral
organizers of membrane domains. They form tetraspa-
nin-enriched microdomains (TEMs) or tetraspanin webs,
in close relation with the cytoskeleton (reviewed in
[153]). TEMs are enriched in cholesterol, GM1 and
sphingolipids, but only a small fraction of the tetraspa-
nins are found in the detergent resistant membrane
(DRM) fractions, unlike raft proteins. Some tetraspanins,
including CD9, CD63, CD81, and CD51 are associated
with PI4K, a kinase that allows the synthesis of PI(4)P,
the main precurssor of PI(4,5)P2. In particular, HIV-Gag
seems to associate specifically with CD63 and CD81 and
less with CD82 [108,109,113-115] while HTLV-1 Gag
associates preferentially with CD82 at the plasma mem-
brane [149-151]. It is noteworthy that CD82 does not
associate with PI4K and that this may be related to the
unusual particle production mode of HTLV, with prefer-
ential budding at the cell-to-cell contact areas and low
production of cell-free virions. One unresolved question
is whether there is a collaboration between rafts and
TEMs during particle assembly or whether distinct bud-
ding microdomains exist in the cell. In support of the
first hypothesis, it was observed that some tetraspanins
are able to address protein complexes toward lipid rafts,
inducing the activation of specific signalization pathways.
In particular, CD81 is necessary to partition the B cell
receptor (BCR) and the CD19/CD21/CD81 complex into
rafts [122,123], while CD82 links the actin cytoskeleton,
T cell receptors and raft domains [124]. This suggests
that tetraspanins may help to target Gag to lipid rafts, or,
the other way around, that Gag could recruit tetraspanins
and lipid raft components in order to activate particular
signalization pathways necessary for sustaining HIV
infection. This later model is supported by recent work
by Krementsov et al. showing the strong trapping of
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CD9 and the transient trapping of cholesterol, GM1 and
CD55 into the HIV-1 assembly microdomains [116].
Interaction between TEMs and lipid rafts could result in
the activation of TCR signalization pathway from which
HIV could benefit. This pathway comprises, for example,
the protein Lck, a Src-kinase participating in T-cell acti-
vation [154], that interacts with HIV-Gag and increases
particle production [155]. Moreover, the activation of
TCR not only causes the accumulation of raft lipids in
the membrane areas involved in the TCR signaling path-
way but also recruits PS, which is probably necessary for
Gag stabilization in PM microdomains during particle
formation [127].
The enriched literature on retroviral assembly has
allowed us to postulate a quite precise model of the
molecular events that drive the anchoring of Gag to cel-
lular membranes preceding particle formation, but these
models remain to be tested experimentally. The high
conservation of the overall process is striking, especially
concerning the specificity of the interaction between
Matrix domain of Gag and cellular lipids (PI(4,5)P2, PS,
cholesterol), and suggests that targeting retroviral
assembly by therapeutical approaches may be a good
strategy to combat HIV infection.
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